A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke

Future Neurology

Volumn 6, Issue 6, 2011, Pages 823-834

  Dhawan, Jasbeer ^a   Benveniste, Helene ^a,b   Luo, Zhongchi ^c   Nawrocky, Marta ^a   Smith, S David ^a   Biegon, Anat ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c St Francis Hospital The Heart Center   (United States)

Author keywords

cognition; d cycloserine; fMRI; infarction; NMDA receptor; stroke

Indexed keywords

CYCLOSERINE; PHOSPHATE BUFFERED SALINE;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ATROPHY; BRAIN INFARCTION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; ELECTROSTIMULATION; FEMALE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; MEMORY; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT;

EID: 80155182128     PISSN: 14796708     EISSN: 17486971     Source Type: Journal    
DOI: 10.2217/fnl.11.55     Document Type: Article

References (75)

1. Carandang R, Seshadri S, Beiser A. Trends in incidence, lifetime risk, severity, and 30-day mortality of stroke over the past 50 years. JAMA 296, 2939-2946 (2006). (Pubitemid 46023453)
2. Rosamond W, Flegal K, Furie K et al. Heart disease and stroke statistics 2008 update a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117, E25-E146 (2008).
3. Wang KM, Kyoung, KP, Yong SK et al. Atherothrombotic middle cerebral artery territory infarction: topographic diversity with common occurrence of concomitant small cortical and subcortical infarcts. Stroke 31, 2055-2061 (2000).
4. Caplan L, Schmahmann J, Kase C et al. Caudate infarcts. Arch. Neurol. 47, 133-143 (1990). (Pubitemid 20058108)
5. Phipps L. Assessment of neurologic deficits in stroke: acute-care and rehabilitation implications. Nurs. Clin. North Am. 26, 957-970 (1991).
6. Albers GW, Clark WM, Madden KP, Hamilton SA: ATLANTIS trial: results for patients treated within 3 hours of stroke onset. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS). Stroke 33, 493-496 (2002).
7. Mitka M. Tensions remain over tPA for stroke. JAMA 289, 1363-1364 (2003). (Pubitemid 37430299)
8. Novak BL, Force RW. Detriments of tPA for acute stroke in routine clinical practice. J. Fam. Pract. 52(2), 95-96 (2003). (Pubitemid 36188080)
9. Hacke W, Kaste M, Bluhmki E. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med. 359, 1317-1329 (2008).
10. Wahlgren N, Ahmed N, Davalos A. Thrombolysis with alteplase 3 to 4.5 hours after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 372, 1303-1309 (2008).
11. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 55, 363-389 (2008).
12. Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke 40, S111-S114 (2009).
13. Benveniste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J. Neurochem. 43, 1369-1374 (1984). (Pubitemid 15205893)
14. Davalos A, Castillo J, Serena J, Noya M. Duration of glutamate release after acute ischemic stroke. Stroke 28, 708-710 (1997). (Pubitemid 27161450)
15. Choi DW, Rothman SM. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu. Rev. Neurosci. 13, 171-182 (1990). (Pubitemid 20100647)
16. Obrenovitch TP, Urenjak J, Zilkha E, Jay TM. Excitotoxicity in neurological disorders-the glutamate paradox. Int. J. Dev. Neurosci. 18, 281-287 (2000). (Pubitemid 30129201)
17. Rod MR, Auer RN. Pre-and post-ischemic administration of dizocilpine (MK-801) reduces cerebral necrosis in the rat. Can. J. Neurol. Sci. 16, 340-344 (1989). (Pubitemid 19213597)
18. Chen M, Bullock R, Graham DI, Frey P, Lowe D, McCulloch J. Evaluation of a competitive NMDA antagonist (d-CPPene) in feline focal cerebral ischemia. Ann. Neurol. 30, 62-70 (1991).
19. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 49, S66-S69 (1997). (Pubitemid 27495612)
20. Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M. Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomized controlled trial. GAIN International Investigators. Lancet 355, 1949-1954 (2000). (Pubitemid 30326099)
21. Sacco RL, DeRosa JT, Haley EC Jr, Levin B, Ordronneau P, Phillips SJ. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA 28, 1719-1728 (2001). (Pubitemid 32259906)
22. Hoyte L, Barber PA, Buchan AM, Hill MD. The rise and fall of NMDA antagonists for ischemic stroke. Curr. Mol. Med. 4(2), 131-136 (2004). (Pubitemid 38425910)
23. Morris RG, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-d-aspartate receptor antagonist, AP5. Nature 319, 774-776 (1986). (Pubitemid 16145031)
24. Kossel AH, Williams CV, Schweizer M, Kater SB. Afferent innervation influences the development of dendritic branches and spines via both activity-dependent and non-activity-dependent mechanisms. J. Neurosci. 17, 6314-6324 (1997). (Pubitemid 27329905)
25. Albensi BC. The NMDA receptor/ion channel complex: a drug target for modulating synaptic plasticity and excitotoxicity. Curr. Pharm. Des. 13(31), 3185-3194 (2007). (Pubitemid 350201695)
26. Obviagle B, Kidwell CS, Satrkama S, Saver JL. Neuroprotective agents for the treatment of acute ischemic stroke. Curr. Neurol. Neuroci. Rep. 3, 9-20 (2003). (Pubitemid 38898978)
27. Biegon A, Fry PA, Padan CM, Alexandrovich A, Tsenter J, Shohami E. Dynamic changes in N-methyl-d-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc. Natl Acad. Sci. USA 101(14), 5117-5122 (2004). (Pubitemid 38469212)
28. Dhawan J, Benveniste H, Nawrocky M, Smith SD, Biegon A. Transient focal ischemia results in persistent and widespread neuroinflammation and loss of glutamate NMDA receptors. Neuroimage 51, 599-605 (2010).
29. Friedman LK, Belayev L, Alfonso OF, Ginsberg MD. Distribution of glutamate and proenkephalin messenger RNAs following transient focal cerebral ischemia. Neuroscience 95(3), 841-857 (2000).
30. Ogawa N, Haba K, Mizukawa K, Asanuma M, Hirata H, Mori A. Loss of N-methyl-d-aspartate (NMDA) receptor binding in rat hippocampal areas at the chronic stage after transient forebrain ischemia: histological and NMDA receptor binding studies. Neurochem. Res. 16(5), 519-524 (1991).
31. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH. d-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed Xenopus oocytes. Brain Res. 510, 158-160 (1990). (Pubitemid 20060820)
32. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniotomy in rats. Stroke 20, 84-91 (1989). (Pubitemid 19040218)
33. Hyder F, Rothman DL, Mason GF, Rangarajan A, Behar KL, Shulman RG. Oxidative glucose metabolism in rat brain during single forepaw stimulation: a spatially localized 1H[13C] nuclear magnetic resonance study. J. Cereb. Blood Flow Metab. 17, 1040-1047 (1997). (Pubitemid 27459331)
34. Luo Z, Mei Y, Smith SD et al. The effect of intravenous lidocane on brain activation during non-noxious and acute noxious stimulation of the forepaw: a functional magnetic resonance imaging study in the rat. Anesth. Analg. 108(1), 334-344 (2009).
35. Ennaceur A, Delacour J. A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav. Brain Res. 31, 47-59 (1988).
36. Hirshler Y, Polat U, Biegon A. Intracranial electrode implantation produces regional neuroinflammation and memory deficits in rats. Exp. Neurol. 222, 42-45 (2010).
37. Memezawa H, Minamisawa H, Smith ML, Siesjo BK. Ischemic penumbra in a model of reversible middle cerebral artery occlusion in the rat. Exp. Brain Res. 89, 67-78 (1992).
38. Memezawa H, Smith ML, Siesjo BK. Penumbral tissues salvaged by reperfusion following middle cerebral artery occlusion in rats. Stroke 23, 552-559 (1992).
39. Spratt NJ, Fernandez J, Chen M et al. Modification of the method of thread manufacture improves stroke induction rate and reduces mortality after thread-occlusion of the middle cerebral artery in young or aged rats. J. Neurosci. Methods 155, 285-290 (2006). (Pubitemid 44233014)
40. Haefelin TN, Kastrup A, de Crespigny A et al. Serial MRI after transient focal cerebral ischemia in rats dynamics of tissue injury, blood-brain barrier damage, and edema formation. Stroke 31, 1965-1973 (2000). (Pubitemid 30620481)
41. Weber R, Ramos-Cabrer P, Hoehn M. Present status of magnetic resonance imaging and spectroscopy in animal stroke models. J. Cereb. Blood Flow Metab. 26, 591-604 (2006).
42. Keilholz SD, Silva AC, Raman M, Merkle H, Koretsky AP. Functional MRI of the rodent somatosensory pathway using multislice echo planar imaging. Magn. Reson. Med. 52, 89-99 (2004). (Pubitemid 39295260)
43. Weber R, Ramos-Cabrer P, Justicia C et al. Early prediction of functional recovery after experimental stroke: functional magnetic resonance imaging, electrophysiology, and behavioral testing in rats. J. Neurosci. 28(5), 1022-1029 (2008). (Pubitemid 351186343)
44. Dijkhuizen, RM, Singhal AB, Mandeville JB et al. Correlation between brain reorganization, ischemic damage, and neurologic status after transient focal cerebral ischemia in rats: a functional magnetic resonance imaging study. J. Neurosci. 23(2), 510-517 (2003). (Pubitemid 36139550)
45. Fishell G, Goldman JE. A silver lining to stroke: does ischemia generate new cortical interneurons? Nat. Neurosci. 13(2), 145-148 (2010).
46. Temple MD, Hamm RJ. Chronic, post-injury administration of d-cycloserine, an NMDA partial agonist, enhances cognitive performance following experimental brain injury. Brain Res. 741, 246-251 (1996). (Pubitemid 26426322)
47. Yaka R, Biegon A, Grigoriadis N et al. d-cycloserine improves functional recovery and reinstates long-term potentiation (LTP) in a mouse model of closed head injury. FASEB J. 21, 2033-2041 (2007). (Pubitemid 47026439)
48. Henrich-Noack P, Baldauf K, Reiser G, Reymann KG. Pattern of time-dependent reduction of histologically determined infarct volume after focal ischaemia in mice, Neurosci. Lett. 432, 141-145 (2008).
49. Rossini PM. Brain redundancy: responsivity or plasticity? Ann. Neurol. 48, 128-129 (2001).
50. Rossini PM, Calautti C, Pauri F, Baron JC. Post-stroke plastic reorganization in the brain. Lancet Neurol. 2, 493-502 (2003).
51. Ji S, Kronenberg G, Balkaya M et al. Acute neuroprotection by pioglitazone after mild brain ischemia without effect on long-term outcome. Exp. Neurol. 216, 321-328 (2009).
52. Mark VW, Taub E, Perkins C, Gauthier L, Uswatte G. MRI infarction load and CI therapy outcomes for chronic post-stroke hemiparesis. Restor. Neurol. Neurosci. 26, 13-33 (2008). (Pubitemid 351630027)
53. Twitchell TE. The restoration of motor function following hemiplegia in man. Brain 74, 443-480 (1951).
54. Mothet JP, Rouaud E, Sinet PM et al. A critical role for the glial-derived neuromodulator d-serine in the age-related deficits of cellular mechanisms of learning and memory. Aging Cell 5, 267-274 (2006). (Pubitemid 43805616)
55. Kim PM. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc. Natl Acad. Sci. USA 102, 2105-2110 (2005). (Pubitemid 40262019)
56. Nitsche MA, Jaussi W, Liebetanz D, Lang N, Tergau F, Paulus W. Consolidation of human motor cortical neuroplasticity by d-cycloserine. Neuropsychopharmacology 29, 1573-1578 (2004). (Pubitemid 38982250)
57. Adeleye A, Shohami E, Nachman D et al. d-cycloserine improves functional outcome after traumatic brain injury with wide therapeutic window. Eur. J. Pharmacol. 629, 25-30 (2010).
58. Laake K, Oeksengaard AR. d-cycloserine for Alzheimer's disease. Cochrane Database Syst. Rev. 2, CD003153 (2002).
59. Duncan E J, Szilagyi S, Schwartz MP et al. Effects of d-cycloserine on negative symptoms in schizophrenia. Schizophr. Res. 1, 239-248 (2004). (Pubitemid 39330502)
60. Heifets LB. Antimycobacterial drugs. Semin. Respir. Infect. 9, 84-103 (1994). (Pubitemid 24286907)
61. Bielenberg GM, Beck T. The effects of dizocilpine (MK-801), phencyclidine, and nimodipine on infarct size 48 h after middle cerebral artery occlusion in the rat. Brain Res. 552, 338-342 (1991).
62. Izumi Y, Roussel S, Pinard E, Seylaz J. Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats. J. Cereb. Blood Flow Metab. 11(6), 1025-1030 (1991).
63. Chen M, Bullock R, Graham DI, Frey P, Lowe D, McCulloch J. Evaluation of a competitive NMDA antagonist (d-CPPene) in feline focal cerebral ischemia. Ann. Neurol. 30, 62-70 (1991).
64. Bullock R, Graham DI, Chen MH, Lowe D, McCulloch J. Focal cerebral ischemia in the cat: pretreatment with a competitive NMDA receptor antagonist, d-CPP-ene. J. Cereb. Blood Flow Metab. 10(5), 668-674 (1990). (Pubitemid 20260948)
65. Dezsi L, Greenberg JH, Sladky J, Araki N, Hamar J, Reivich M. Prolonged effects of MK-801 in the cat during focal cerebral ischemia and recovery: Survival, EEG activity and histopathology. J. Neurol. Sci. 121(1), 110-120 (1994). (Pubitemid 24025254)
66. Yam PS, Dunn LT, Graham DI, Dewar D, McCulloch J. NMDA receptor blockade fails to alter axonal injury in focal cerebral ischemia. J. Cereb. Blood Flow Metab. 20, 772-779 (2000). (Pubitemid 30317051)
67. Reggiani A, Pietra C, Arban R et al. The neuroprotective activity of the glycine receptor antagonist GV150526: an in vivo study by magnetic resonance imaging. Eur. J. Pharm. 419(2-3), 147-153 (2001). (Pubitemid 32568213)
68. Ohtani K, Tanaka H, Ohno Y. SM-31900, a novel NMDA receptor glycine-binding site antagonist, reduces infarct volume induced by permanent middle cerebral artery occlusion in spontaneously hypertensive rats. Neurochem. Int. 42(5), 375-384 (2003). (Pubitemid 36044670)
69. Oda M, Kure S, Sugawara T et al. Direct correlation between ischemic injury and extracellular glycine concentration in mice with genetically altered activities of the glycine cleavage multienzyme system. Stroke 38, 2157-2164 (2007). (Pubitemid 47012283)
70. Albers GW, Atkinson RP, Kelley RE, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl-d-aspartate antagonist dextrorphan in patients with acute stroke. Stroke 26, 254-258 (1995).
71. Dyker AG, Lees KR. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke. Stroke 30, 1796-1801 (1999). (Pubitemid 29411817)
72. Davis SM, Lees KR, Albers GW et al. Selfotel in acute ischemic stroke: possible neurotoxic effects of an NMDA antagonist. Stroke 31, 347-354 (2000). (Pubitemid 30078164)
73. Albers GW, Goldstein LB, Hall D, Lesko LM. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. JAMA 286, 2673-2682 (2001). (Pubitemid 33135073)
74. Lees KR, Dyker AG, Sharma A, Ford GA, Ardron ME, Grosset DG. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study. Stroke 32, 466-472 (2001). (Pubitemid 32155236)
75. Haley EC Jr, Thompson JL, Levin B et al.; GAIN Americas and GAIN International Investigators. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke 36(5), 1006-1010 (2005). (Pubitemid 40629293)